Acute alterations in glucose homeostasis impact coronary microvascular function in patients presenting with ST-segment elevation myocardial infarction

M. A. van Lavieren · M. Bax · V. E. Stegehuis · T. P. van de Hoef · G. W. M. Wijntjens · R. J. de Winter · K. T. Koch · J. P. S. Henriques · M. Meuwissen · K. D. Sjauw · J. J. Piek

Published online: 17 January 2020
© The Author(s) 2020

Abstract

Background Microvascular dysfunction in the setting of ST-segment myocardial infarction (STEMI) is thought to be related to stress-related metabolic changes, including acute glucose intolerance. The aim of this study was to assess the relationship between admission glucose levels and microvascular function in non-diabetic STEMI patients.

Methods 92 consecutive patients with a first anterior-wall STEMI treated with primary percutaneous coronary intervention (PPCI) were enrolled. Blood glucose levels were determined immediately prior to PPCI. After successful PPCI, at 1-week and 6-month follow-up, Doppler flow was measured in culprit and reference coronary arteries to calculate coronary flow velocity reserve (CFVR), baseline (BMR) and hyperaemic (HMR) microvascular resistance.

Results The median admission glucose was 8.3 (7.2–9.6) mmol/l respectively 149.4 mg/dl [129.6–172.8] and was significantly associated with peak troponin T (standardised beta coefficient [std beta] = 0.281; p= 0.043). Multivariate analysis revealed that increasing glucose levels were significantly associated with a decrease in reference vessel CFVR (std beta = –0.313; p= 0.002), dictated by an increase in rest average peak velocity (APV) (std beta = 0.216; p= 0.033), due to a decreasing BMR (std beta = –0.225; p= 0.038) in the acute setting after PPCI. These associations disappeared at follow-up. These associations were not found for the infarct-related artery.

Conclusion Elevated admission glucose levels are associated with impaired microvascular function assessed directly after PPCI in first anterior-wall STEMI. This influence of glucose levels is an acute phenomenon and contributes to microvascular dysfunction through alterations in resting flow and baseline microvascular resistance.

What’s new?

- Major stress-related metabolic changes occur in the first hours after ST-segment elevation myocardial infarction (STEMI), leading to glucose intolerance in some patients
- Elevated glucose levels and glucose intolerance are associated with an increased risk of mortality, heart failure and cardiogenic shock and no-reflow phenomenon in the culprit vessel
- Elevated admission glucose levels in the setting of STEMI are associated with impaired microvascular function in non-culprit vessels at baseline
- Larger STEMI’s with higher Troponin T levels are associated with higher glucose levels, which may be associated with microvascular dysfunction in non-culprit vessels
Keywords  ST-elevation myocardial infarction · microvascular dysfunction · acute glucose intolerance

Introduction

It is well recognised that even after rapid and successful revascularisation of ST-segment elevation myocardial infarction (STEMI), myocardial tissue perfusion remains compromised in 30–40% of patients despite restored epicardial patency [1, 2]. This phenomenon is attributed to microvascular dysfunction in the setting of acute STEMI [3], which is observed in both the perfusion territory of the culprit artery, and in non-ischaemic regions remote from the infarcted myocardial tissue [4]. Whereas culprit vessel flow abnormalities have been ascribed to numerous pathophysiological mechanisms, it has partly been ascribed to metabolic consequences of the acute ischemic event [5, 6].

Major stress-related metabolic changes occur during the early hours of STEMI, which include the release of stress hormones such as noradrenaline and cortisol, increased concentration of free fatty acids, and the occurrence of glucose intolerance [7]. As a result, elevated glucose levels are frequently observed in (non-diabetic) STEMI patients, which have been associated with an increased risk of in-hospital mortality, congestive heart failure and cardiogenic shock in patients with and without diabetes [8, 9]. Notably, in patients with STEMI, hyperglycaemia is associated with the no-reflow phenomenon in the culprit vessel, postulated to be a proxy of microvascular dysfunction [10]. It suggests that the acute metabolic changes in STEMI may contribute to microvascular dysfunction in this setting through alterations in glucose homeostasis.

The aim of this study was to assess the relationship between admission glucose levels and microvascular function in non-diabetic patients with first anterior-wall STEMI.

Methods

A total of 100 consecutive patients with a first anterior-wall STEMI treated by primary percutaneous coronary intervention (PPCI) were enrolled. The initial results were reported previously [4, 11]. STEMI was defined as chest pain lasting >30 minutes in the presence of persistent ST-segment elevation in ≥2 precordial leads. PPCI was performed within 6 hours after onset of symptoms according to standard clinical practice. The exclusion criteria were reported previously [4]. The study protocol was approved by the local ethics committee and all patients gave informed consent.

Cardiac catheterisation and periprocedural measurements

After successful reperfusion, intracoronary blood flow velocity was measured in the infarct-related artery (IRA) and an angiographic normal reference vessel (diameter stenosis <30% on visual estimation) using a 0.014-inch sensor equipped guide wire (Volcano Corp., San Diego, CA). Reference vessel measurements were performed in the left circumflex coronary artery, or the right coronary artery if a stenosis of >30% was present. At 1-week and 6-month follow-up, patients underwent repeat angiography with assessment of intracoronary Doppler flow velocity. Hyperaemia was induced by an intracoronary bolus of 20–40 µg adenosine. Before and after PCI, coronary angiography suitable for quantitative coronary angiographic analysis was performed for offline analysis of thrombolysis in myocardial infarction (TIMI) flow and myocardial blush grade. Left ventricular function was evaluated by means of echocardiographic 16-segment Wall Motion Score Index (WMSI) performed immediately before PPCI.

Haemodynamic data analysis

Coronary flow velocity reserve (CFVR) was calculated as the ratio of hyperaemic average peak flow velocity (hAPV) to baseline average peak velocity (bAPV). In the absence of significant epicardial disease in the reference vessels, microvascular resistance was calculated at baseline and during hyperaemia, respectively the ratio between mean aortic pressure and mean distal flow velocity at baseline (baseline microvascular resistance—BMR), and during hyperaemia (hyperaemic microvascular resistance—HMR). The delta microvascular resistance from resting to hyperaemic conditions (dMR) was determined by calculating the absolute difference between BMR and HMR.

Statistical analysis

Normality of the data was tested using the Shapiro-Wilk test, and homogeneity of variance was tested with Levene’s test. All continuous variables are presented as mean ± standard deviation or median [25th–75th percentile] according to their normal or non-normal distribution. Categorical variables are presented as counts and percentages. Univariate regression analysis was used to identify variables associated with reference vessel CFVR at the end of the PPCI procedure (P_{inclusion}<0.1), with candidate variables including all baseline, laboratory and procedural covariates as listed in Tab. 1. Subsequent multivariate analysis was performed using a multivariate linear regression model with adjustments for these variables to identify the association of glucose levels with microvascular function parameters, which are presented as standardised coefficients to facilitate
Table 1  Baseline clinical and procedural characteristics (n = 92)

Demographics
- Age, y: 56 ± 12
- Male: 74 (80)

Risk factors
- Smoking: 49 (53)
- Hypertension: 23 (25)
- Family history: 39 (42)
- Hyperlipidaemia: 24 (26)
- Prior medication use
  - β-Blocker: 12 (13)
  - Calcium antagonist: 8 (9)
  - Angiotensin-converting enzyme inhibitors: 5 (5)
  - Nitrates: 4 (4)
  - Lipid-lowering drugs: 7 (8)
  - Aspirin: 11 (12)

Prior medication use

Laboratory assessment at admission
- CRP, mg/l: 1.9 [1.1–5.2]
- Glucose, mmol/l: 8.3 [7.2–9.6]
- Creatinine, µmol/l: 70 [60–79]
- NT-proBNP after reperfusion, pg/ml: 93 [49–242]
- Peak troponin T after 24 hours, ng/ml: 4.58 [2.47–6.34]

Procedural characteristics
- Heart rate, bpm: 79 ± 13
- Systolic arterial pressure, mm Hg: 119 ± 15
- WMSI before reperfusion: 1.9 ± 0.2
- Time to reperfusion, h: 2.9 [2.3–3.9]
- ST-segment resolution after reperfusion ≥70%: 40 (43)

Angiographic
- Final TIMI flow grade 3: 56 (60)
- Final myocardial blush grade 3: 37 (40)

Data are presented as mean ± SD, median [25th–75th percentile], or frequency (%). CRP C-reactive protein, eGFR estimated glomerular filtration rate, NT-proBNP N-terminal pro-brain natriuretic peptide, TIMI thrombolysis in myocardial infarction, WMSI Wall Motion Score Index

Table 2  Haemodynamic characteristics

Infarct-related artery at admission (n = 92)
- Final IRA CFVR
  - Baseline APV, cm per second: 19 [14–24]
  - Hyperaemic APV, cm per second: 29 [21–42]

Infarct-related artery at 1 week (n = 62)
- Final IRA CFVR
  - Baseline APV, cm per second: 21 ± 7
  - Hyperaemic APV, cm per second: 37 [30–44]

Infarct-related artery at 6 months (n = 61)
- Final IRA CFVR
  - Baseline APV, cm per second: 17 ± 7
  - Hyperaemic APV, cm per second: 48 ± 19

Reference vessel haemodynamics at admission (n = 91)
- Reference CFVR
  - Baseline APV, cm per second: 16 [14–20]
  - Hyperaemic APV, cm per second: 37 [31–45]

Baseline MR, mm Hg/cm per second: 7.2 [6.2–8.8]
- Hyperaemic MR, mm Hg/cm per second: 3.1 [2.6–3.8]
- Delta MR, mm Hg/cm per second: 4.0 [3.3–5.4]

Reference vessel haemodynamics at 1 week (n = 62)
- Reference CFVR
  - Baseline APV, cm per second: 2.7 ± 0.5
  - Hyperaemic APV, cm per second: 44 [35–53]

Baseline MR, mm Hg/cm per second: 6.6 [5.4–8.4]
- Hyperaemic MR, mm Hg/cm per second: 2.5 [2.1–3.0]
- Delta MR, mm Hg/cm per second: 4.2 [3.4–5.4]

Reference vessel haemodynamics at 6 months (n = 61)
- Reference CFVR
  - Baseline APV, cm per second: 3.4 ± 0.6
  - Hyperaemic APV, cm per second: 15 [10–21]

Baseline MR, mm Hg/cm per second: 8.9 [6.2–11.3]
- Hyperaemic MR, mm Hg/cm per second: 2.5 [2.0–3.0]
- Delta MR, mm Hg/cm per second: 6.0 [4.1–8.3]

Values are presented as mean ± SD or median [25th–75th percentile]. APV average peak flow velocity, CFVR coronary flow velocity reserve, IRA infarct-related artery, MR microvascular resistance

Results

In total, 92 patients were included in the study (Tab. 1). Median admission glucose was 8.3 mmol/l [7.2–9.6] respectively 149.4 mg/dl [129.6–172.8] and was significantly associated with infarct size (standardised beta coefficient [std beta] = 0.281; p = 0.043), as determined by peak troponin T levels. After PPCI, IRA TIMI 3 flow was achieved in 65 patients (70%). Intracoronary physiological measurements obtained in the IRA and reference vessel are presented in Tab. 2.

Association between admission glucose and microvascular function after PPCI

No association was found between admission glucose levels with CFVRIRA, as well as bAPVIRA or hAPVIRA measured directly after revascularisation.

CFVRreference decreased significantly with increasing admission glucose levels (std beta = −0.381; p < 0.001). In addition, bAPVreference increased significantly with increasing admission glucose levels (std beta = 0.244; p = 0.020), and BMRreference decreased with admission glucose levels (std beta = −0.257; p = 0.015). Consequently, dMRreference decreased with increasing admission glucose levels (std beta = −0.325; p = 0.002) (Fig. 1). hAPVreference as well as HMRreference did not show a significant association with admission glucose levels.
Fig. 1 Scatterplots of admission glucose levels with microvascular function in the reference vessel after PPCI. Admission glucose levels were significantly associated with coronary flow velocity reserve (a), bAPV (b), BMR (c) and dMR (d) in the reference vessel in the acute setting of STEMI (PPCI primary percutaneous coronary intervention, CFVR_{ref} reference vessel coronary flow velocity reserve, bAPV_{ref} reference vessel baseline averaged peak velocity, BMR_{ref} reference vessel baseline microvascular resistance, dMR_{ref} reference vessel delta microvascular resistance)

Univariate analysis of all candidate baseline, laboratory and procedural covariates as listed in Tab. 1. Age, heart rate, peak troponin T after 24 hours, WMSI assessed before PPCI, and the use of calcium antagonists were associated with CFVR_{reference}. After adjustment for these variables, admission glucose level remained independently associated with CFVR_{reference} (std beta = –0.313; \(p = 0.002\)), bAPV_{reference} (std beta = 0.216; \(p = 0.033\)), BMR_{reference} (std beta = –0.225; \(p = 0.038\)) and dMR_{reference} (std beta = –0.274; \(p = 0.008\)) (Tab. 3).

Association between admission glucose and microvascular function at 1-week and 6-month follow-up

At one week follow-up, intracoronary physiology measurements in the IRA and reference vessel were repeated in 62 patients (Tab. 2). No significant association was found between admission glucose levels and CFVR_{IRA}, bAPV_{IRA}, as well as hAPV_{IRA} measured at 1-week follow-up.

Univariate analysis revealed that admission glucose was significantly associated with CFVR_{reference} (std beta = –0.284; \(p = 0.025\)), BMR_{reference} (std beta = –0.280; \(p = 0.029\)), and dMR_{reference} (std beta = –0.295; \(p = 0.021\)). However, after adjustment for the identified confounders, none of these variables retained a significant association.

At 6-month follow-up, intracoronary physiology measurements in the IRA and reference vessel were repeated in 61 patients (Tab. 2). Univariate analysis revealed that admission glucose at times of the PPCI was only associated with CFVR_{reference} measured at 6-month follow-up, although this association was eclipsed after adjusting for the identified confounders. Univariate analysis revealed no association between admission glucose levels, BAPV, hAPV and CFVR at 6-month follow-up.

Discussion

We observed that increased admission glucose levels in the acute setting of STEMI are independently associated with alterations in microvascular function, par-
We found no association between microvascular function and admission glucose levels in the IRA. The influence of admission glucose levels on the parameters of microvascular function was likely eclipsed by other physiological processes that alter microvascular function in the IRA during the acute setting of STEMI.

### Microvascular function following STEMI: novelty of the present findings

Microvascular function assessed by Doppler flow velocity is known to be altered in the setting of STEMI, even in non-ischaemic regions at distance from the infarcted myocardium [4]. We previously reported that microvascular dysfunction in these regions is expressed in an impairment of reference vessel CFVR, which is independently associated with long-term fatal cardiac events [11]. We showed that the acute

| Table 3 Association between reference CFVR and glucose by univariate and multi-variate analysis at admission, 1-week and 6-month follow-up |
| --- |
| **At admission (n=92)** | **At 1-week follow-up (n=61)** | **At 6-month follow-up (n=61)** |
| | Univariable analysis | Multivariable analysis | | Univariable analysis | Multivariable analysis | | Univariable analysis | Multivariable analysis | |
| **CFVR in reference vessel** | | | | | | | | |
| Glucose | $-0.381$ | $<0.001$ | $-0.313$ | 0.002 | – | – | – | – |
| Age | $-0.254$ | 0.015 | – | – | – | – | – | – |
| Heart rate | $-0.225$ | 0.034 | – | – | $-0.413$ | 0.002 | – | – |
| Peak troponin T (after 24h) | $-0.469$ | $<0.001$ | $-0.355$ | 0.002 | – | – | – | – |
| WMSI | $-0.265$ | 0.014 | – | – | – | – | $-0.278$ | 0.042 |
| Calcium antagonist | $-0.381$ | $<0.001$ | – | – | – | – | – | – |
| **Baseline APV in reference vessel** | | | | | | | | |
| Glucose | 0.244 | 0.02 | 0.216 | 0.033 | – | – | – | – |
| Age | – | – | – | – | – | – | – | – |
| Heart rate | – | – | – | – | – | – | – | – |
| Peak troponin T (after 24h) | 0.241 | 0.026 | – | – | – | – | – | – |
| WMSI | 0.316 | 0.003 | 0.266 | 0.014 | – | – | – | – |
| Calcium antagonist | 0.349 | 0.001 | 0.385 | $<0.001$ | – | – | – | – |
| **Baseline MR in reference vessel** | | | | | | | | |
| Glucose | $-0.257$ | 0.015 | $-0.225$ | 0.038 | – | – | – | – |
| Age | – | – | – | – | – | – | – | – |
| Heart rate | $-0.262$ | 0.02 | $-0.229$ | 0.045 | $-0.269$ | 0.044 | – | – |
| Peak troponin T (after 24h) | $-0.228$ | 0.038 | – | – | $-0.346$ | 0.022 | – | – |
| WMSI | $-0.326$ | 0.003 | $-0.246$ | 0.035 | – | – | – | – |
| Calcium antagonist | $-0.295$ | 0.006 | $-0.292$ | 0.008 | – | – | – | – |
| **Delta MR in reference vessel** | | | | | | | | |
| Glucose | $-0.325$ | 0.002 | $-0.274$ | 0.008 | – | – | – | – |
| Age | – | – | – | – | – | – | – | – |
| Heart rate | $-0.318$ | 0.004 | $-0.244$ | 0.023 | $-0.320$ | 0.015 | – | – |
| Peak troponin T (after 24h) | $-0.376$ | $<0.001$ | – | – | $-0.336$ | 0.022 | – | – |
| WMSI | $-0.357$ | 0.001 | $-0.223$ | 0.041 | – | – | – | – |
| Calcium antagonist | $-0.299$ | 0.005 | $-0.247$ | 0.016 | – | – | – | – |

Std beta standardised beta coefficient, CFVR coronary flow velocity reserve, APV average peak velocity, MR microvascular resistance, WMSI Wall Motion Score Index
impairment of reference vessel CFVR in the setting of STEMI originates from a combination of decreased bAPV in the presence of increased HMR, and increased bAPV in the presence of decreased BMR. It has been hypothesised that a combination of mechanical and metabolic alterations due to the acute ischaemic event is responsible for the overall flow impairment at a distance of the infarcted myocardium. The increase in HMR leading to impairment of hyperaemic flow is generally attributed to neurohumoral overactivation [5]. A reduced BMR leading to an increased resting coronary flow may underlie a mechanical as well as a metabolic origin, which is yet to be elucidated. Our present results attribute at least part of the decrease in BMR, and the resulting increase in basal flow velocity, to metabolic changes in the setting of acute STEMI reflected in hyperglycaemia.

Glucose and insulin mediated microvascular dysfunction

Increased glucose levels are frequently observed in non-diabetic patients presenting with acute myocardial infarction. It reflects the conjoined effects of many interrelated stress mechanisms that influence glucose homeostasis secondary to the acute ischaemic event [7, 16]. Relative insulin resistance is proposed as one of the contributing mechanisms, caused by antagonising effects of stress mediators that impair insulin-regulated glucose uptake [17, 18]. Concomitantly, insulin plays an important role as a mediator in normal myocardial and systemic vascular function [19]. It has been demonstrated to increase myocardial blood flow, acting as a slow vasodilator inducing vasodilation in a time and dose dependent manner [20–22]. In patients with coronary artery disease, intracoronary insulin infusion increases coronary blood flow in the absence of an increase in myocardial oxygen demand [20]. The most important physiological mechanism that contributes to insulin-induced vasodilation is the L-arginine to nitric oxide pathway in the vascular endothelium [23]. Despite the effects of insulin resistance on glucose uptake and resulting hyperglycaemia, it has been shown that the insulin-induced coronary vasodilation still occurs in obese patients with insulin resistance [24]. Therefore, the association observed between myocardial microvascular function and admission glucose levels might reflect the effect of elevated plasma levels of insulin, secondary to acute relative insulin resistance, on myocardial vascular function. Unfortunately, plasma insulin levels were not measured in the present study and the proposed mechanism of action should be considered hypothesis-generating.

Concomitant causes of increased baseline flow velocity in STEMI

In addition to the influence of alterations in glucose homeostasis on microvascular function, and in particular bAPV and BMR, other factors may have had a concomitant effect on bAPV. Due to regional myocardial dysfunction, hyperkinesia of remote non-ischaemic myocardium may occur, leading to a predominant increase in bAPV due to an increase in local myocardial oxygen demand [25, 26]. In addition, an increase in left ventricular end-diastolic pressure or stiffening of the myocardium because of hypoxic perfusion, may result in a restriction in myocardial capacitance, leading to an isolated increase in reference vessel bAPV [27, 28]. Nonetheless, the association between admission glucose levels and the bAPV retained significance after adjusting for the identified confounders, including infarct size WMSI which can be considered important predictors for the magnitude of hyperkinesia, left ventricular end-diastolic pressure and hypoxic perfusion.

Implications for the present study

The present study implies that admission glucose levels are associated with reference vessel microvascular function in the acute setting of STEMI, influencing resting coronary vascular tone and increasing resting flow. Importantly, increased bAPV has previously been documented to be associated with impaired clinical outcomes in both stable coronary artery disease and STEMI [11, 29]. Due to the role of insulin in establishing glucose homeostasis and altering vascular tone, we hypothesise that high insulin levels, secondary to acute insulin resistance, are the mechanism of action responsible for the increase in bAPV. Recovery of this phenomenon at follow-up likely drives recovery of normal coronary autoregulatory function. The fact that larger myocardial infarctions, as determined by troponin T levels, were associated with higher glucose levels, as well as with higher resting flow levels, suggests that the severity of the acute ischaemic event determines the magnitude of metabolic disturbance, and is thereby indirectly related to the magnitude of pan-myocardial microvascular dysfunction.

Limitations

Accurate assessment of flow velocity depends on the operator’s experience, and, furthermore, on the achievement of maximal vasodilation. The measurements in this study were performed by experienced operators. The amount of adenosine used in this study is considered sufficient [30].

We only assessed reference vessel microvascular resistance in coronary arteries without angiographically significant epicardial narrowing using aortic pressure as a substitute for distal pressure.
In this study, glucose levels were only measured at admission and were not repeated at 1-week and 6-month follow-up. This did not allow for exploration of the time course of glucose levels in the period following myocardial infarction. In addition, insulin levels were not determined at any of the time points, resulting in the fact that the hypothesised mechanism could not be further elucidated. Subjects were excluded based on known pre-existing diabetes at the time of admission, however, information on the HbA1C levels was not available to reveal unknown pre-existing impaired glucose homeostasis. Additionally, the study population was relatively small, in particular at 6-month follow-up, and some statistical analyses may lack statistical significance because of a lack of statistical power.

**Conclusion**

Elevated glucose levels at admission for anterior STEMI are associated with impaired microvascular function in myocardial territories remote from the infarction, as assessed by CFVR in reference coronary arteries measured after PPCI. This influence of glucose levels is an acute phenomenon dominantly affecting coronary autoregulation, affecting BMR and bAPV, and contributes to the pan-myocardial microvascular dysfunction observed in acute STEMI.

**Conflict of interest** M.A. van Lavieren, M. Bax, V.E. Stegehuis, T.P. van de Hoef, G.W.M. Wijntjens, R.J. de Winter, K.T. Koch, J.P.S. Henriques, M. Meuwissen, K.D. Sjauw and J.J. Piek declare that they have no competing interests.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the origin authors(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Dibra A, Mehilli J, Dirschinger J, et al. Thrombolysis in myocardial infarction myocardial perfusion grade in angiography correlates with myocardial salvage in patients with acute myocardial infarction treated with stenting or thrombolysis. J Am Coll Cardiol. 2003;41:925–9.
2. Tarantini G, Cacciavillani L, Corbetti F, et al. Duration of ischemia is a major determinant of transmurality and severe microvascular obstruction after primary angioplasty: a study performed with contrast-enhanced magnetic resonance. J Am Coll Cardiol. 2005;46:1229–35.
3. Ito H, Okamura A, Iwakura K, et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation. 1996;93:1993–9.
4. Bax M, de Winter RJ, Koch KT, et al. Time course of microvascular resistance of the infarct and noninfarct coronary artery following an anterior wall acute myocardial infarction. Am J Cardiol. 2006;97:1131–6.
5. Schäfer U, Kurz T, Jain D, et al. Impaired coronary flow and left ventricular dysfunction after mechanical recanalization in acute myocardial infarction: role of neurohumoral activation? Basic Res Cardiol. 2002;97:399–408.
6. Rezkalla SH, Kloner RA. Coronary no-reflow phenomenon. Curr Treat Options Cardiovasc Med. 2005;7:75–80.
7. Oliver MF, Opie LH. Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lancet. 1994;343:155–8.
8. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet. 2000;355:773–8.
9. Vis MM, Sjauw KD, van der Schaaf RJ, et al. In patients with ST-segment elevation myocardial infarction with cardiogenic shock treated with percutaneous coronary intervention, admission glucose level is a strong independent predictor for 1-year mortality in patients without a prior diagnosis of diabetes. Am Heart J. 2007;154:1184–90.
10. Iwakura K, Ito H, Ikushima M, et al. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol. 2003;41:1–7.
11. van de Hoef TP, Bax M, Meuwissen M, et al. Impact of coronary microvascular function on long-term cardiac mortality in patients with acute ST-segment elevation myocardial infarction. Circ Cardiovasc Interv. 2013;6:207–15.
12. de Bruyne B, Bartunek J, Sys SU, et al. Simultaneous coronary pressure and flow velocity measurements in humans. Feasibility, reproducibility, and hemodynamic dependence of coronary flow velocity reserve, hyperemic flow versus pressure slope index, and fractional flow reserve. Circulation. 1996;94:1842–9.
13. Wienke H, Haude M, Ge J, et al. Corrected coronary flow velocity reserve: a new concept for assessing coronary perfusion. J Am Coll Cardiol. 2000;35:1713–20.
14. van de Hoef TP, Nolte E, Echavarría-Pinto M, et al. Impact of hyperaemic microvascular resistance on fractional flow reserve measurements in patients with stable coronary artery disease: insights from combined stenosis and microvascular resistance assessment. Heart. 2014;100:951–9.
15. Fearon WF, Shah M, Ng M, et al. Predictive value of the index of microcirculatory resistance in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2008;51:560–5.
16. Diaz R, Paolasso EA, Piegas LS, et al. Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiológicos Latinoamérica) Collaborative Group. Circulation. 1998;98:2227–34.
17. de Alvaro C, Tereul T, Hernandez R, et al. Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK dependent manner. J Biol Chem. 2004;279:17070–8.
18. Kim J, Yeh DC, Ver M, et al. Phosphorylation of Ser24 in the pleckstrin homology domain of insulin receptorsubstrate-1 by Mouse Pelle-like kinase/interleukin-1 receptor-associated kinase: cross-talk between inflammatory signaling and insulin signaling that may contribute to insulin. J Biol Chem. 2005;280:23173–83.
19. Baron AD. Hemodynamic actions of insulin. Am J Physiol. 1994;267:E187–202.
20. McNulty PH, Pfau S, Deckelbaum LI. Effect of plasmainsulin level on myocardial blood flow and its mechanism of action. Am J Cardiol. 2000;85:161–5.
21. Rocchini AP, Wilson RE, Marker P, et al. Metabolic and hemodynamic effects of a graded intracoronary insulin infusion in normal and fat anesthetized dogs: a preliminary study. Hypertension. 1996;27:354–9.
22. Sundell J, Nuutila P, Laine H, et al. Dose-dependent vasodilating effects of insulin on adenosine-stimulated myocardial blood flow. Diabetes. 2002;51:1125–30.
23. Sobrevia L, Yudilevich DL, Mann GE. Activation of A2-purinoceptors by adenosine stimulates L-arginine transport (system y+) and nitric oxide synthesis in human fetal endothelial cells. J Physiol. 1997;499(Pt 1):135–40.
24. Sundell J, Laine H, Luotolahti M, et al. Obesity affects myocardial vasoreactivity and coronary flow response to insulin. Obes Res. 2002;10:617–24.
25. Lew WY, Chen ZY, Guth B, et al. Mechanisms of augmented segment shortening in nonischemic areas during acute ischemia of the canine left ventricle. Circ Res. 1985;56:351–8.
26. Lew WY. Influence of ischemic zone size on nonischemic area function in the canine left ventricle. Am J Physiol. 1987;252:H990–7.
27. Watanabe J, Levine MJ, Bellotto F, et al. Left ventricular diastolic chamber stiffness and intramyocardial coronary capacitance in isolated dog hearts. Circulation. 1993;88:2929–40.
28. Van Herck PL, Carlier SG, Claes MJ, et al. Coronary microvascular dysfunction after myocardial infarction: increased coronary zero flow pressure both in the infarcted and in the remote myocardium is mainly related to left ventricular filling pressure. Heart. 2007;93:1231–7.
29. van de Hoef TP, Bax M, Damman P, et al. Impaired coronary autoregulation is associated with long-term fatal events in patients with stable coronary artery disease. Circ Cardiovasc Interv. 2013;6:329–35.
30. De Bruyne B, Pijls NHJ, Barbato E, Heyndrickx GR, et al. Intracoronary and intravenous adenosine 5′-triphosphate, adenosine, papaverine, and contrast medium to assess fractional flow reserve in humans. Circulation. 2003;107:1877–83.
Advertisement placed here.
Advertisement placed here.

Houten 2019